Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
Mouse IL-7, amino acids Glu26 -Ile154 (Accession# NM_008371.4) was expressed in insect cells.
The 148 amino acid recombinant protein (with ADL-His9-SSGIEGR at N-terminus) has a predicted molecular mass of approximately 17 kD. The DTT-reduced and non-reduced protein migrates at approximately 20 kD by SDS-PAGE.
>95%, as determined by Coomassie stained SDS-PAGE.
The protein was 0.22 µm filtered in 10 mM NaH2PO4, 150 mM NaCl, pH 7.2.
Less than 0.01 ng per µg cytokine as determined by the LAL method.
10 µg and 25 µg sizes are bottled at 100 µg/mL.
Storage & Handling:
Unopened vial can be stored at 4°C for three months or from -20°C to -70°C for six months. For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 µg/mL in sterile buffer containing carrier protein such as 1% BSA or HSA or 10% FBS. After dilution, the cytokine can be stored at 4°C for one month or from -20°C to -70°C for up to 3 months. Avoid repeated freeze/thaw cycles.
ED50 =1.0 - 5 ng/ml, corresponding to a specific activity of 0.2 - 1 x 106 units/mg, as determined by PHA activated PBL proliferation induced by IL-7 in a dose dependent manner. Under this condition the bioactivity is equivalent
PHA activated PBL proliferation induced by mouse IL-7.
Mouse IL-7 was initially described as a pre B-cell grow factor expressed in bone marrow stromal cells. IL-7 is essential for normal murine B cell development, and plays a key role in regulating the homeostasis and function of the T-cells. The binding of IL-7 to its receptor induces dimerization of IL-7Ra and the common gamma chain (gc) which leads to activation of receptor associated tyrosine Janus kinases JAK1 (IL-7R) and JAK3 (γc). The activated JAK proteins in turn phosphorylate specific residues on the IL-7R creating docking sites for signaling molecules such as STAT5 and to a lesser extent STAT1 and STAT3. In adult mice, IL-7/IL-7R signaling up regulates expression of early B cell factor (EBF), and EBF in turn regulates expression of B cell-specific genes required for the transition from lymphoid progenitor to pro-B cells. Besides, IL-7 plays a role in the development of secondary lymphoid tissues. IL-7 is necessary to specify CD8 lineage differentiation during CD4/CD8 cell fate choice in the thymus by inducing expression of the transcription factor Runx3. IL-7 induces anti-apoptotic factors Bcl2 and Bcl-xL and inhibiting pro-apoptotic factors such as Bad and Bax. In this fashion, IL-7 induces cell activation, survival, and proliferation of T lymphocytes. In addition, IL-7 controls T-cell size and metabolism through the activation of PI3 kinase-dependent pathways and regulation of glucose metabolism. IL-7 also controls T cell–dendritic cell interactions that are essential for both T-cell homeostasis and activation in vivo. CD4 T cell lymphopenia increases the expression of circulating IL-7, and TGFb induces IL-7 downregulation.
Thymic and bone morrow stromal cells, keratinocytes, dendritic cells, endothelial cells, intestinal epithelial, and epithelial goblet cells.
IL-7 is essential for B cell production.
Heterodimer IL-7Rα (CD127); γ-subunit (CD132) which shares component with IL-2, IL-4, IL-13, IL-15, and IL-21 receptors.
Progenitor B and T cells, CD4-CD8- thymocytes, naïve and memory CD4 and CD8 T cells, and megakaryocytes.
1. Yokota T, et al. 1986. P. Natl. Acad. Sci. USA 83:5894. 2. Meier D, et al. 2007. Immunity 26:643. 3. Parish JK, et al. 2009 J. Immunol. 182:4255. 4. Saini M, et al. 2009. Blood 113:5793. 5. Park JH, et al. 2010. Nat. Immunol. 11:257. 6. Li WQ, et al. 2010. Mol. Cell. Biol. 30:590.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.